Literature DB >> 29934817

Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome.

Mariela Mosheva1,2, Virginie Pouillard3, Yael Fishman4, Lydia Dubourg3, Dafna Sofrin-Frumer4, Yaffa Serur4, Abraham Weizman5,6, Stephan Eliez3,7, Doron Gothelf4,5,8, Maude Schneider3.   

Abstract

22q11.2 deletion syndrome (22q11.2DS) is the most common known microdeletion in humans occurring in 1 out of 2000-4000 live births, with increasing numbers of individuals with the microdeletion living into adulthood. The aim of the study was to explore the education and employment trajectories of individuals with 22q11.2DS from childhood to adulthood in a large cohort composed of two significant samples. 260 individuals with 22q11.2DS, 134 male and 126 female, aged 5-59 years (mean age 21.3 ± 10.8 years) were evaluated at two sites, Geneva (GVA) and Tel Aviv (TA). Psychiatric comorbidities, IQ score, and adaptive functioning were assessed using gold-standard diagnostic tools. Demographic factors, such as data about education, employment, marital status, and living status, were collected. Children entering elementary school (5-12 years) were significantly more likely to attend a mainstream school, while adolescents were significantly more likely to attend special education schools (p < 0.005). Cognitive abilities, and not adaptive functioning, predicted school placement. Among adults with 22q11.2DS (n = 138), 57 (41.3%) were unemployed, 46 (33.3%) were employed in open market employment, and 35 (25.4%) worked in assisted employment. In adulthood, adaptive functioning more than cognitive abilities predicted employment. Surprisingly, psychotic spectrum disorders were not found to be associated with employment. Individuals with 22q11.2DS are characterized by heterogeneity in educational and employment profiles. We found that cognitive abilities and adaptive functioning, and not the presence of psychiatric disorders, are key factors in school placement and employment. These factors should, therefore, be taken into account when planning optimal development of individuals with 22q11.2DS.

Entities:  

Keywords:  Adaptive functioning; Education; Employment; Psychosis; Schizophrenia; VABS; Velocardiofacial syndrome

Mesh:

Year:  2018        PMID: 29934817     DOI: 10.1007/s00787-018-1184-2

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  30 in total

1.  Neurocognitive profile in 22q11 deletion syndrome and schizophrenia.

Authors:  Eva W C Chow; Mark Watson; Donald A Young; Anne S Bassett
Journal:  Schizophr Res       Date:  2006-06-06       Impact factor: 4.939

2.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.

Authors:  J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-07       Impact factor: 8.829

3.  Age-dependent clinical problems in a Norwegian national survey of patients with the 22q11.2 deletion syndrome.

Authors:  Kari Lima; Ivar Følling; Kristin L Eiklid; Solveig Natvig; Tore G Abrahamsen
Journal:  Eur J Pediatr       Date:  2010-02-26       Impact factor: 3.183

4.  Presenting symptoms in adults with the 22q11 deletion syndrome.

Authors:  Annick Vogels; Sara Schevenels; Richard Cayenberghs; Eddy Weyts; Griet Van Buggenhout; Ann Swillen; Hilde Van Esch; Thomy de Ravel; Pieter Corveleyn; Koen Devriendt
Journal:  Eur J Med Genet       Date:  2014-02-24       Impact factor: 2.708

Review 5.  Community participation of people with an intellectual disability: a review of empirical findings.

Authors:  M M L Verdonschot; L P de Witte; E Reichrath; W H E Buntinx; L M G Curfs
Journal:  J Intellect Disabil Res       Date:  2008-12-11

Review 6.  Velo-cardio-facial syndrome: 30 Years of study.

Authors:  Robert J Shprintzen
Journal:  Dev Disabil Res Rev       Date:  2008

7.  An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11.2 deletion syndrome.

Authors:  Kathleen Angkustsiri; Ingrid Leckliter; Nicole Tartaglia; Elliott A Beaton; Janice Enriquez; Tony J Simon
Journal:  J Dev Behav Pediatr       Date:  2012 Nov-Dec       Impact factor: 2.225

8.  Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome.

Authors:  Tamar Green; Doron Gothelf; Bronwyn Glaser; Martin Debbane; Amos Frisch; Moshe Kotler; Abraham Weizman; Stephan Eliez
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-11       Impact factor: 8.829

Review 9.  Practical guidelines for managing adults with 22q11.2 deletion syndrome.

Authors:  Wai Lun Alan Fung; Nancy J Butcher; Gregory Costain; Danielle M Andrade; Erik Boot; Eva W C Chow; Brian Chung; Cheryl Cytrynbaum; Hanna Faghfoury; Leona Fishman; Sixto García-Miñaúr; Susan George; Anthony E Lang; Gabriela Repetto; Andrea Shugar; Candice Silversides; Ann Swillen; Therese van Amelsvoort; Donna M McDonald-McGinn; Anne S Bassett
Journal:  Genet Med       Date:  2015-01-08       Impact factor: 8.822

10.  The clinical presentation of attention deficit-hyperactivity disorder (ADHD) in children with 22q11.2 deletion syndrome.

Authors:  Maria Niarchou; Joanna Martin; Anita Thapar; Michael J Owen; Marianne B M van den Bree
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-09-24       Impact factor: 3.568

View more
  9 in total

1.  Medical, welfare, and educational challenges and psychological distress in parents caring for an individual with 22q11.2 deletion syndrome: A cross-sectional survey in Japan.

Authors:  Ryo Morishima; Yousuke Kumakura; Satoshi Usami; Akiko Kanehara; Miho Tanaka; Noriko Okochi; Naomi Nakajima; Junko Hamada; Tomoko Ogawa; Shuntaro Ando; Hidetaka Tamune; Mutsumi Nakahara; Seiichiro Jinde; Yukiko Kano; Kyoko Tanaka; Yoichiro Hirata; Akira Oka; Kiyoto Kasai
Journal:  Am J Med Genet A       Date:  2021-09-03       Impact factor: 2.578

Review 2.  Clinical evaluation of patients with a neuropsychiatric risk copy number variant.

Authors:  Samuel Jra Chawner; Cameron J Watson; Michael J Owen
Journal:  Curr Opin Genet Dev       Date:  2021-01-15       Impact factor: 4.665

Review 3.  A cross-comparison of cognitive ability across 8 genomic disorders.

Authors:  Michael Mortillo; Jennifer G Mulle
Journal:  Curr Opin Genet Dev       Date:  2021-05-31       Impact factor: 4.665

4.  Need for psychiatric phenotyping in patients with rare genetic disorders.

Authors:  Franziska Degenhardt; Gertraud Gradl-Dietsch; Johannes Hebebrand
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-03       Impact factor: 4.785

5.  Utility of Measuring Fetal Cavum Septum Pellucidum (CSP) Width During Routine Obstetrical Ultrasound for Improving Diagnosis of 22q11.2 Deletion Syndrome: A Case-Control Study.

Authors:  Christy L Pylypjuk; Shiza F Memon; Bernard N Chodirker
Journal:  Appl Clin Genet       Date:  2022-07-26

Review 6.  Deletion Syndrome 22q11.2: A Systematic Review.

Authors:  Jonathan Cortés-Martín; Nuria López Peñuela; Juan Carlos Sánchez-García; Maria Montiel-Troya; Lourdes Díaz-Rodríguez; Raquel Rodríguez-Blanque
Journal:  Children (Basel)       Date:  2022-08-03

7.  From Learning to Memory: A Comparison Between Verbal and Non-verbal Skills in 22q11.2 Deletion Syndrome.

Authors:  Johanna Maeder; Mathilde Bostelmann; Maude Schneider; Karin Bortolin; Matthias Kliegel; Stephan Eliez
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 4.157

Review 8.  Consequences of 22q11.2 Microdeletion on the Genome, Individual and Population Levels.

Authors:  Małgorzata Karbarz
Journal:  Genes (Basel)       Date:  2020-08-22       Impact factor: 4.096

9.  Relationship between intelligence quotient measures and computerized neurocognitive performance in 22q11.2 deletion syndrome.

Authors:  Ruben C Gur; Tyler M Moore; Ronnie Weinberger; Ehud Mekori-Domachevsky; Raz Gross; Beverly S Emanuel; Elaine H Zackai; Edward Moss; Robert Sean Gallagher; Daniel E McGinn; Terrence Blaine Crowley; Donna McDonald-McGinn; Doron Gothelf; Raquel E Gur
Journal:  Brain Behav       Date:  2021-07-02       Impact factor: 2.708

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.